HAS evaluation of HIPEC with or without cytoreductive surgery
In 2019, AMARAPE committed to making patients’ voices heard and gaining recognition for the specific treatment of rare peritoneal tumors, cytoreductive surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). AMARAPE participated in the work of evaluating professional practices by the French National Authority for Health (HAS) as a patient association, and several members provided their testimonials.
The objective of this work was twofold:
- to evaluate the efficacy and safety of HIPEC associated with prior cytoreduction in order to define which indications are validated/not validated;
- to define the conditions for performing HIPEC associated with prior cytoreduction and the subsequent hospitalization, as well as the necessary preoperative preparation and post-hospitalization follow-up procedures.
This work was carried out with a view to possible inclusion in the Common Classification of Medical Procedures (CCAM) for coverage by the French national health insurance system. The procedure was based on work published by the scientific community.
In June 2021, the HAS published its conclusions and this assessment concerning patients with rare peritoneal tumors (pseudomyxomas and peritoneal mesotheliomas).
– Opinion No. 2021.0041/AC/SEAP of June 17, 2021, from the Haute Autorité de Santé (HAS) college on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with or without prior cytoreductive surgery: link to the opinion
-Decision No. 2021.0168/DC/SEAP of June 17, 2021, of the Haute Autorité de Santé college adopting the technology assessment report entitled “Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with or without prior cytoreductive surgery”: link to the HAS college decision
– Evaluation report on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with or without prior cytoreductive surgery: link to the technology assessment report
AMARAPE takes action following the closure of the Lariboisière expert center
AMARAPE members mobilized with the director of the AP-HP and their representatives in early 2019 following the closure of Professor Pocard’s department, the RENAPE expert center, announced in spring 2018 and effective in October 2018 without relocation. Following this mobilization, six written questions were submitted to the Minister of Solidarity and Health by MPs JM Mis, O Faure, J Giraud, V Lacroute, B Brocard, and A Bergé.
A response was provided at the end of July 2019.
It reiterates the response provided to AMARAPE by the director of AP-HP in April 2019. Read the letter.
The new medical organization for digestive surgery comprises two AP-HP sites with two managers (Professor Pocard at Lariboisière and Professor Goéré at St Louis). Professor Pocard will ensure the continuity of consultations at Lariboisière, with a secretarial office remaining in place. St Louis will focus on AP-HP’s digestive oncology care.
AMARAPE remains vigilant and will keep you informed.